Collectively, these findings indicate the potential predictive value of combining genomic and transcriptomic data analysis to determine the degree of R-spondin upregulation in prostate cancer and the requirement for further work to explore if R-spondin signaling coordinates tumor-stroma interactions to facilitate tumorigenesis and/or therapeutic resistance. This evidence concerns the gene RSPO1 and Familial prostate cancer.